Get notified when SLXN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Auditors and management express substantial doubt about ability to continue operations; cash of $2.4M sufficient for only several months without additional financing.
- Nasdaq Delisting Risk - Mandatory Monitoring (new) — Under mandatory Nasdaq panel monitoring until September 2026; any shareholders' equity deficiency triggers immediate delisting proceedings with no cure period. Currently below $2.5M minimum equity requirement.
Silexion Therapeutics prices $2.5M offering at $0.65/share, 65% below recent market price
Filed August 13, 2026 · ~2 min read
Key Changes
-
high
Offering 2,028,619 shares plus up to 1,817,542 pre-funded warrants at $0.65/unit (65% discount to $1.87 last market price), raising $2.3M net proceeds to the company after fees.
The Offering verify on EDGAR → -
high
Net proceeds of $2.3M will fund pre-clinical and clinical studies and general corporate purposes. Company has $2.4M cash, $11.9M GAAP net loss for 2025, and $57.9M accumulated deficit.
Use of Proceeds; Management's Discussion and Analysis view on EDGAR → -
high
Auditors express substantial doubt about ability to continue as going concern; current cash sufficient for only several months. Under mandatory Nasdaq monitoring until Sept 2026 with no cure period if equity falls below $2.5M.
Risk Factors; Experts view on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.
Partner
Trade SLXN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 16, 2026 · How we verify